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SUMMARY

Necrotizing enterocolitis (NEC) is a deadly intestinal inflammatory disorder that primarily affects premature
infants and lacks adequate therapeutics. Interleukin (IL)-22 plays a critical role in gut barrier maintenance,
promoting epithelial regeneration, and controlling intestinal inflammation in adult animal models. However,
the importance of IL-22 signaling in neonates during NEC remains unknown. We investigated the role of
IL-22 in the neonatal intestine under homeostatic and inflammatory conditions by using a mouse model of
NEC. Our data reveal that Il22 expression in neonatal murine intestine is negligible until weaning, and both
human and murine neonates lack IL-22 production during NEC. Mice deficient in IL-22 or lacking the IL-22
receptor in the intestine display a similar susceptibility to NEC, consistent with the lack of endogenous IL22 during development. Strikingly, treatment with recombinant IL-22 during NEC substantially reduces
inflammation and enhances epithelial regeneration. These findings may provide a new therapeutic strategy
to attenuate NEC.
INTRODUCTION
The length of gestation in mammals has evolved to allow appropriate fetal growth suitable for postnatal life. Shortened in utero
development, such as in the context of prematurity, exposes
the newborns to a plethora of pathologies inherent to the immaturity of their organs.1,2 One such devastating disease is necrotizing enterocolitis (NEC), one of the most prevalent and lethal
neonatal emergencies associated with prematurity.3 NEC is an
intestinal inflammatory disorder characterized by the impairment
of the epithelial barrier and leading, in the most extreme cases, to
intestinal perforation and tissue necrosis, which require surgical
intervention.3 Despite decades of intensive research, the pathogenesis of NEC remains obscure, thus hampering the development of effective therapeutic strategies and leaving the clinicians
in the neonatal intensive care unit (NICU) unarmed against this
deadly disease. It is widely accepted that NEC is triggered by
dysbiosis of colonizing microorganisms, which invade the
immature intestine of premature neonates.4,5 In the setting of
prematurity, intestinal epithelial cells express high levels of
Toll-like receptor 4 (TLR4), rendering them prone to the induction
of an exaggerated inflammatory response upon colonization

with microorganisms.6 Several studies have demonstrated that
the onset of NEC is preceded by a significant increase of Gammaproteobacteria.7–9 More specifically, a recent metagenomic
study conducted by Olm et al. revealed that an abundance of
Klebsiella and Fimbriae-encoding bacteria are present in the
stools of infants prior to the clinical symptoms of NEC.9 However, the impact of these changes on intestinal homeostasis and
the integrity of the intestinal mucosa remains to be explored.
Interleukin-22 (IL-22), a cytokine belonging to the IL-10 family, is
an essential modulator of intestinal microbial communities and
can control intestinal homeostasis by preventing harmful inflammatory responses in adults.10 IL-22 is mainly produced by CD4+
T cells and group 3 innate lymphoid cells (ILC3s) and promotes
the expression of several antimicrobial factors, including regenerating islet-derived proteins (Reg) REG3B and REG3G, b-defensins, and S100 proteins.11–14 These antimicrobial proteins shape
the intestinal microbiome to prevent the development of chronic
inflammatory disorders and contribute to the clearance of harmful
pathogens.12–14 Similarly, by enhancing the fucosylation of epithelial cells,15–17 IL-22 obviates the expansion of the opportunistic
pathogen Enterococcus faecalis and dampens the expression of
bacterial virulence factors during murine experimental colitis.16,17
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Figure 1. Neonatal intestinal immune cells
display low levels of IL-22 production
(A and B) Il22 (A) and Il22ra1 (B) gene expression
was quantified in the terminal ileum of embryonic
day 15 (e15) and e17, as well as postnatal days 1, 4,
7, 14, 21, 28, and 49, mice (n = 3 embryonic mice,
n = 10 postnatal mice as biological replicates per
group).
(C) IL-22 intracellular staining of LP cells isolated
from the small intestine of 1- and 8-week-old mice.
Data are representative of two independent experiments.
(D) Percentage of CD45+IL22+ cells in the small intestine.
Data are displayed as mean ± SEM. Results were
analyzed using a Mann-Whitney test. **p < 0.01.

In addition to the prevention of intestinal inflammation through
the modulation of the microbiome, IL-22 can stimulate epithelial
cell regeneration following intestinal insults via the proliferation of
epithelial cells and the activation of anti-apoptotic pathways in
adult animals.18–22 While the importance of IL-22 in protecting
against adult intestinal inflammation has been extensively
documented, the role of IL-22 in neonates has not been widely
investigated. Investigators have shown that an influx of IL-22producing ILC3s can provide resistance against neonatal
pneumonia.23 Moreover, IL-22 reduced pancreatic enzyme
expression, leading to the lethality and growth retardation of
newborn IL-23 transgenic mice.24 Interestingly, Shindo et al.
found that mice carrying a CFLAR transgene encoding for the
caspase-8/FADD-like IL-1b-converting enzyme (FLICE)-inhibitory proteins that regulate cell-death-receptor-mediated
apoptosis displayed severe neonatal ileitis.25 They further
discovered that activated ILC3s produced IL-22 and were
responsible for apoptosis, but not necroptosis, of intestinal
epithelial cells.25 Taken together, these reports highlight the versatile function of IL-22 in different neonatal pathological settings;
however, the role of IL-22 in the context of NEC has not been
studied. In the current study, we aimed to investigate the role
of IL-22 signaling during neonatal NEC.
RESULTS
The neonatal period is characterized by a lack of IL-22
production in the intestine
To unravel the role of IL-22 in the pathogenesis of NEC, we first
determined the expression of Il22 in the small intestine of mice
throughout the first weeks of life. We demonstrated that the preand postnatal expression of Il22 in the terminal ileum is relatively
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low and starts to increase at the time of
weaning (Figure 1A). In addition, the expression of the IL-22 receptor subunit alpha 1
(IL22ra1) slightly increased during development (Figure 1B). These data were further
confirmed by assessing the percentage of
IL-22-producing cells in the small intestine
lamina propria (LP) of neonatal pups and
adult mice. The percentages of CD45+ cells
that express IL-22 in LP of newborn mice were significantly lower
(0.03% ± 0.01%) than those found in the LP of adult mice (1.17% ±
0.94%) (Figures 1C, 1D, and S1). Interestingly, we found that the
damaged terminal ileum of neonatal mice subjected to an experimental NEC protocol through formula feeding and hypoxia treatment (NEC) did not exhibit increased expression levels of Il22
when compared to the dam-fed (DF) pups (Figures 2A and 2B).
We also found that the induction of NEC in mouse pups was associated with a significant reduction of the IL-22 receptor expression
(Figure 2B). On the other hand, the analysis of human NEC intestinal samples did not reveal any difference in IL-22RA1 expression
between NEC and non-NEC (control) groups (Figure 2D). These
data suggest that intestinal prematurity is associated with the
inability to efficiently produce IL-22 under both homeostatic and
inflammatory conditions.
Deficiency in intestinal epithelial IL-22 signaling does
not affect the susceptibility to NEC
Previous studies have shown that IL-22 deficiency leads to
increased susceptibility of adult mice to intestinal inflammation.12–17 Given that experimental NEC was not associated
with an upregulation of Il22, we reasoned that a deficiency in
IL-22 signaling might not increase the severity of experimental
NEC. To test this hypothesis, we subjected newborn pups lacking the expression of the Il22 receptor in intestinal epithelial cells
(IL-22ra1fl/fl; Vil cre+) and their wild-type (WT) littermates (IL22ra1fl/fl; Vil cre) to experimental NEC. Induction of experimental NEC resulted in a significant upregulation of Il1b in WT
mice compared to DF mice (Figure 2E). In addition, mice subjected to experimental NEC that carried a conditional deletion
of Il22ra1, specifically in intestinal epithelial cells (IL-22ra1fl/fl;
Vil cre+), had similar expression levels of Il1b to their WT
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Figure 2. IL-22 signaling deficiency does not increase NEC susceptibility
(A) Representative histology of the small intestine of dam-fed (DF) pups (left panel) or pups that have been subjected to a NEC protocol (NEC, right panel). Scale
bar, 200 mm.
(B) Il22 and Il22ra1 expression in the terminal ileum of DF mice and pups subjected to experimental NEC.
(C) Representative histology of non-NEC control and NEC human infant small intestine. Scale bar, 200 mm.
(D) Expression levels of IL22 (left panel) or IL22RA1 (right panel) in the ileum of infants with NEC and non-NEC controls.
(E) Effect of intestinal epithelial-specific IL22ra1 deficiency on Il1b expression in the intestine of DF pups and mice subjected to experimental NEC. Data were
combined from independent experiments.
(F) Representative H&E staining of terminal ileum sections from each genotype. Scale bar, 200 mm.

(legend continued on next page)
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littermates (IL-22ra1fl/fl; Vil cre; Figure 2E). Histological assessment of NEC-like small intestinal injury showed that the disease
severity was similar in IL-22ra1fl/fl Vil cre+ and IL-22ra1fl/fl Vil cre
mice (Figures 2F and 2G). We next sought to investigate the effect of IL-22 germline deletion on the development of NEC. In
accordance with our previous observations, IL-22 deficiency
did not alter the susceptibility of neonatal mice to NEC, as IL22KO mice exhibited similar small intestine expression of Il1b
(Figure 2H) and mucosal injury as compared to mice in the WT
group (Figures 2I and 2J). Interestingly, WT and IL-22 KO pups
did not display a significant difference in epithelial cell proliferation during NEC (Figure S2). Taken together, these data demonstrate that IL-22 deficiency does not affect the outcome of NEC
in newborn mice, likely because of the inefficiency of the
neonatal immune cell compartment to mount an appropriate
IL-22-mediated anti-inflammatory response with IL-22 to counteract the detrimental inflammation.
rIL-22 administration reduces NEC severity and
enhances epithelial barrier regeneration
Given the inability of neonates to mount an efficient IL-22 response
during NEC, we asked whether treatment with IL-22 could protect
against the development of the disease. In mice subjected to NEC,
those treated with recombinant murine IL-22 (rIL-22) displayed
significantly lower mRNA levels of the pro-inflammatory markers
Il1b and C-X-C motif chemokine ligand 2 (Cxcl2) compared to littermates injected with phosphate-buffered saline (PBS) (Figure 3A). Moreover, we found that IL-22 treatment was associated
with a significant reduction of IL-1b production in ileal samples
when compared to the PBS control group (Figure 3A). On the other
hand, the expression levels of Cxcl1 in the intestines of IL-22treated pups were similar to those in the vehicle control group (Figure 3A). In addition to the reduction of inflammatory factors, IL-22
treatment resulted in reduced disease severity, as shown by the
decreased percentage of mucosal damage in comparison to
PBS-treated pups (Figures 3B and 3C). To determine whether
the protective role of rIL-22 is mediated through the activation of
IL-22 signaling in epithelial cells, we experimentally induced
NEC in IL-22ra1fl/fl; Vil cre+ and IL-22ra1fl/fl; Vil cre pups along
with IL-22 or PBS treatments (Figure S3). In line with our hypothesis, we found that IL-22 treatment in WT pups (IL-22ra1fl/fl; Vil
cre) resulted in a significant downregulation of Il1b and Cxcl2
(Figures S3A and S3B) and improved histologic appearance (Figure S3C) compared to the PBS control group. In contrast, the deletion of the Il22ra1 gene in IL-22ra1fl/fl; Vil cre+ pups resulted in the
suppression of IL-22-mediated protection, as suggested by the
similar expression levels of Il1b and Cxcl2 (Figures S3A and
S3B) and the similar appearance of epithelial destruction seen in
the rIL-22- and PBS-treated pups (Figure S3C).
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In light of published reports that demonstrate that IL-22 protects
the intestine of adult mice through the enhancement of epithelial
cell regeneration,20 we sought to assess the impact of IL-22 treatment on the regeneration of the neonatal epithelial barrier. Immunostaining of the ileum revealed that IL-22 treatment promotes a
significant expansion of proliferating cell nuclear antigen
(PCNA)+ cells (Figures 3D and 3E), whereas the number of Olfactomedin 4 (OLFM4+) stem cells was unchanged (Figure 3D). These
data suggest that treatment with IL-22 attenuates experimental
NEC by promoting the proliferation of epithelial cells and improving
epithelial regeneration. To further understand the impact of IL-22
treatment on the intestinal epithelial barrier, we have also analyzed
the integrity of the tight junctions (TJs) in the intestinal epithelium
through immunofluorescent staining of the intestinal specimens
with anti-occludin antibody (Figure S4). The cross-sectional images of the epithelial cells in DF pups showed a clear membrane
localization of occludin. A similar staining pattern was observed
in intestinal epithelial cells of pups subjected to NEC and treated
with IL-22. On the other hand, the occludin staining of epithelial
cells in the PBS-treated NEC group displayed a more diffused
cytoplasmic localization, suggesting impairment of the TJs. Taken
together, our data demonstrate that in addition to the enhancement of epithelial cell regeneration, IL-22 treatment protects the
integrity of the intestinal epithelial barrier during NEC.
IL-22 treatment triggers an antimicrobial transcriptional
program in the neonatal small intestine
To better understand the cellular modifications initiated by IL-22,
we investigated the differential gene expressions induced by IL22 treatment in intestinal enteroids and compared them to those
observed in the small intestine of adult mice lacking IL-22ra1 in the
epithelial cell compartment (IL-22ra1fl/fl; Vil cre+ versus IL22ra1fl/fl; Vil cre). RNA sequencing transcriptional analysis
showed that treatment of enteroids with rIL-22 triggers an antimicrobial response in vitro and in vivo, as shown by the upregulation
of several genes such as Retnlb, Reg3g, Fut2, and S100 genes,
which are all known to be involved in the regulation of the microbiome (Figure 4A). To validate these findings, we treated enteroids
cultured from the small intestine of neonatal mice with rIL-22 and
found that treatment upregulated Retnlb, Reg3g, and Fut2 (Figure 4B). We also found that IL-22 treatment of neonatal mice leads
to a significant upregulation of antimicrobial genes including
Retnlb, Reg3g, and Fut2 in both DF pups and pups subjected to
experimental NEC (Figure 4C). Similarly, IL-22 treatment of human enteroids cultured from premature infant ileum led to an upregulation of REG3G, whereas it slightly reduced the expression
of RETNLB (Figure 4D). These data indicate that IL-22 treatment
can trigger an antimicrobial response in the small intestine of
neonatal mice and premature infants.

(G) Histological score of the intestinal lesions in pups subjected to NEC (n = 11–15 per group). Histological scores are displayed as mean ± SEM as the percentage
of lesion extent from the total length of the entire tissue section.
(H) Effect of IL-22 deficiency on Il1b expression in the intestine of DF pups and neonatal mice subjected to NEC. Data were combined from at least three independent experiments.
(I) Representative H&E staining of terminal ileum sections from each genotype. Scale bar, 200 mm.
(J) Histological score of the intestinal lesions in the experimental NEC pups (n = 7–8 per group).
All data are presented as mean ± SEM percentage of lesion extent from the total length of the tissue section. All gene expression data are displayed as mean ±
SEM and were analyzed using a Mann-Whitney test. **p < 0.01, ***p < 0.001.
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Figure 3. IL-22 treatment attenuates experimental NEC by enhancing epithelial cell regeneration
(A) Four-day-old pups were either subjected to the NEC protocol or kept with the dams as controls for 3 days. The pups received a daily i.p. injection of recombinant IL-22 (rIL-22, 100 mg/kg) or an equivalent volume of PBS. Expression levels of Il1b, Cxcl1, and Cxcl2 were measured in the terminal ileum of the pups
after 3 days of PBS or IL-22 treatment. Data were combined from at least three independent experiments.
(B) Representative H&E staining of terminal ileum sections from each experimental group. Scale bar, 200 mm.
(C) Histological score of the intestinal lesions in pups subjected to NEC and either PBS or rIL-22 injections (n = 6–9 per group). Data are presented as mean ± SEM
percentage of lesion extent from the total length of the tissue section.
(D) Representative confocal images of ileal samples of pups with NEC and indicated treatments stained with antibodies against proliferating cell nuclear antigen
(PCNA, green) and Olfactomedin 4 (OLFM4, red). The nuclei were stained with Hoechst (blue). Scale bar, 50 mm.
(E) Quantification of epithelial cell proliferation in the terminal ilea of pups with NEC treated with rIL-22 or PBS.
All gene expression data are displayed as mean ± SEM and were analyzed using Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 4. IL-22 treatment induces an antimicrobial transcriptional program in the small intestine of neonates
(A) Heatmap analysis showing the differential gene expression of adult mouse small intestinal enteroids cultured in the presence of rIL-22 (100 ng/mL) or an
equivalent volume of PBS for 24 h (left column) as well as the small intestine of adult of IL22ra1fl/fl Vil cre+ and IL22ra1fl/fl Vil cre mice (right column).
(B) qPCR quantification of Retnlb, Reg3g, and Fut2 expression in neonatal mouse intestinal enteroids cultured in the presence of rIL-22 (2 ng/mL) or an equivalent
volume of PBS for 24 h. Data are representative of three independent experiments.

(legend continued on next page)
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IL-22 treatment is not associated with a modification of
intestinal microbial communities during experimental
NEC
Our data showed that IL-22 treatment upregulates the antimicrobial peptide Reg3g in the intestinal epithelium. Reg3g has been
shown to play an essential role in protecting the intestinal mucosa
of adult mice via the modulation of different bacterial species.12,13
Therefore, we next assessed the impact of Reg3g treatment on the
severity of experimental NEC. We observed no difference in small
intestine Il1b expression in the pups subjected to NEC that
received PBS injections when compared to pups treated with recombinant Reg3g (rReg3g) (Figure 5A). Moreover, the histological
analysis revealed no impact of Reg3g treatment on intestinal injury,
suggesting that Reg3g antimicrobial activity is not required for the
IL-22-mediated protection against NEC (Figures 5B and 5C). In a
complementary approach, pups were given a Reg3g neutralizing
antibody or an isotype control via oral gavage along with an intraperitoneal (i.p.) injection of IL-22 or PBS (Figure S5). In line with our
previous findings, our data showed that the neutralization of Reg3g
did not abrogate the protection mediated by IL-22, as shown by
the similar expression levels of Il1b in the pups with experimental
NEC treated with rIL-22 or PBS. Taken together, these data suggest that Reg3g antimicrobial activity is not required for IL-22mediated protection against NEC. We next performed a genomic
analysis of microbial composition and diversity to gain further
insight into the impact of the IL-22-driven antimicrobial response
on the composition of the microbiome. As expected, the most
frequent species detected in the experimental NEC groups belong
to the Enterobacter genus, with Enterobacter cloacae being the
most abundant species (Figure 5D). This is consistent with the
fact that Enterobacteriaceae is the predominant species in the intestinal content isolated from the infant with severe NEC that has
been used to induce a NEC-like disease in our neonatal mouse
model.26 The comparison of the microbial species between the
IL-22-treated group and the PBS control pups that were subjected
to NEC did not show any significant differences (Figure 5D). These
data were further confirmed by the calculation of the Shannon,
Chao1, and Simpson indices, which reflect the diversity and the
richness of microbial species (Figures 5E and 5F). These parameters were not significantly altered by IL-22 treatment when
compared to the experimental NEC group treated with PBS. Our
data revealed no difference in the relative abundance of Enterobacter, Escherichia, or Klebsiella species between rIL-22- and
PBS-treated groups during experimental NEC (Figure S6). Taken
together, these data demonstrate that IL-22-mediated protection
against NEC is not associated with an alteration of intestinal microbial composition in an experimental model of NEC and suggest
that it is independent of the IL-22-driven antimicrobial response.
DISCUSSION
In the absence of an effective therapeutic, NEC remains a major
challenge in the NICU with a high mortality rate. With the growing
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literature supporting the important role of IL-22 in protecting the
adult intestinal barrier against inflammatory insults, it seems intuitive to hypothesize a similar protective role of IL-22 in premature
infants affected by NEC. Therefore, a better understanding of the
role of IL-22 in preserving the intestinal barrier of neonates may
lay the ground for a future therapeutic strategy against this
devastating disease. Hence, in the current study, we aimed to
explore the role of IL-22 in neonatal intestinal epithelial cells
and to determine the impact of IL-22 on the outcome of NEC in
a murine model of the disease. Over the last decades, several rodent models have been developed to decipher the pathobiology
of NEC.27 Different methods have been adopted to induce a
NEC-like disease consisting of chemical ablation of Paneth cells,
the use of dextran sulfate sodium (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) or a combination of asphyxia and formula feeding along with oral administration of enteric bacteria
and/or lipopolysaccharide. The mouse model used in the current
study, which uses a human enteric dysbiotic bacteria mixture
cultured from a human NEC patient, offers the advantage of
studying the interaction between the human microbiota and
the immature intestine in neonatal mice. Moreover, a transcriptional analysis carried out in our laboratory revealed that our
mouse NEC model (unpublished data) shares several pathological signaling pathways with the human disease.28
Our developmental time course study revealed that IL-22
expression levels in the intestine were very low in embryonic
mouse intestine and increased slightly after birth, but significantly
increased at weaning, which coincides with a dramatic change of
the enteric microbial composition. Indeed, studies with germ-free
mice have shown that the induction of IL-22 depends on intestinal
colonization with commensal microbes.29,30 It is well accepted
that early life is characterized by a low microbial diversity consisting mainly of facultative anaerobic species, especially in preterm
infants.31 As a consequence, it is possible that neonates lack the
microbial species responsible for the development of IL-22-producing cells. These data are in line with a previous study that utilized an IL-22 reporter mouse to show that IL-22 expression was
low in the intestinal T cells, NKp46+ ILC3s, and lymphoid-tissue
inducer (LTi) cells of newborn pups when compared to those
found in the intestine of adult mice.32 In addition, the authors
have shown that a subset of intestinal macrophages—characterized by their high expression levels of Il23a, Il6, and Tnfa upon
activation with the TLR9 agonist CpG oligonucleotide—harbored
the most potential of inducing IL-22 in neonatal mice prior to
weaning. Interestingly, Gribar et al. have shown that CpG-mediated activation results in reduced NEC severity in a murine
model.33 Moreover, we have previously shown that oral treatment
with the probiotic Lactobacillus rhamnosus prevents the development of NEC in neonatal mice and premature piglets through the
activation of TLR9 by unmethylated CpG dinucleotide of
L. rhamnosus DNA.34 However, whether this TLR9-mediated protection conferred by L. rhamnosus against NEC is achieved
through the enhancement of IL-22 production remains unknown.

(C) Impact of IL-22 treatment on ileal expression of Retnlb, Reg3g, and Fut2 in DF pups and pups subjected to NEC. All gene expression data are displayed as
mean ± SEM and were analyzed using Mann-Whitney test. Data were combined from at least three independent experiments.
(D) Gene expression of RETNLB and REG3G in human neonatal intestinal enteroids treated for 24 h with PBS, 1, 10, or 100 ng/mL of human rIL-22. Unpaired
Student’s t test was used for this analysis. *p < 0.05, **p < 0.01, ****p < 0.0001.
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Figure 5. Antimicrobial response initiated by IL-22 in the small intestine does not impact the composition of the intestinal microbiome
(A) DF pups and pups subjected to NEC received a daily i.p. injection of recombinant Reg3g (rReg3g, 2 ng/pup) or an equivalent volume of PBS. Expression levels
are shown of Il1b in the terminal ileum of either DF or pups subjected to NEC plus PBS or rReg3g.
(B) Representative H&E staining of terminal ileal sections from each experimental group. Scale bar, 200 mm.
(C) Histological score of the intestinal lesions in pups subjected to NEC and treated with PBS or IL-22 (n = 8–11 per group).
(D) Microbial community composition of colon contents collected from pups with NEC injected with PBS or rIL-22 (NEC + rIL-22).
(E) Shannon, Chao1, and Simpson indices demonstrating overall bacterial diversity in the microbiome of a subset of pups with NEC injected with either PBS or rIL22 (NEC + rIL-22).

(legend continued on next page)
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The inability of neonates to mount an effective response to
produce IL-22 is also likely inherent to postnatal immunosuppression. An analysis of the LP cells in newborn mice shows
that the vast majority of CD4+ T cells display a naive phenotype
prior to weaning.35 This effect was attributed to different cell
types such as T regulatory cells, CD71+ erythroid cells, and
myeloid-derived suppressor cells, which are particularly enriched in newborns and likely to play a key role in preventing
the development of detrimental inflammation upon colonization
with enteric microbes.35–37 The role of IL-22 in preventing intestinal injury in murine models of adult inflammatory bowel disease
has been well documented over the last decade.10 As a result of
intestinal inflammation, the induction of IL-22 promotes the
maintenance of mucosal integrity and prevents the damage
caused by colitogenic bacteria.12 Hence, the impairment of
IL-22 signaling in adult mice lacking the expression of IL-22 or
IL-22 receptor (IL-22ra1) leads to increased intestinal damage
upon Citrobacter rodentium infection.12,17 Our data demonstrated that unlike adult mice, neonates do not possess the ability to trigger the production of IL-22 during NEC-mediated
inflammation. Consequently, neonatal pups deficient in either
Il-22 or the receptor IL-22Ra1 do not exhibit enhanced
susceptibility to the disease. Therefore, this inability to mount
an appropriate IL-22 response during intestinal inflammation
might increase the susceptibility of the premature infant to intestinal damage and rapid onset of necrosis in the setting of NEC.
This assumption is supported by the amelioration of NEC-mediated inflammation following treatment with exogenous IL-22, as
defined by the downregulation of pro-inflammatory marker
expression, improvement in histologic architecture, and reduction in histological scores. These findings are supported by previous reports showing the benefit of IL-22 treatment in reducing
the severity of adult intestinal inflammatory disorders.12–17
IL-22 signaling has been shown to trigger a regeneration program leading to the repair of an impaired epithelial barrier.18–20
Early investigations suggested that this is achieved by the
expansion of the intestinal stem cell compartment,18–20 while
recent studies challenged these findings and identified that
epithelial barrier regeneration is the result of enhanced proliferation of the transit amplifying (TA) cells, which are defined by the
expression of a proliferation marker such as PCNA.21,22 Our data
were in accordance with the second line of evidence, as the protective role of IL-22 against NEC was dependent on IL-22Ra1
signaling in the intestinal epithelium and was associated with
increased numbers of proliferating cells rather than an expansion
of the intestinal stem cells. In parallel to the implication of IL-22
involvement in mucosal wound healing, we demonstrate that
IL-22 treatment also induces the expression of several genes
involved in antimicrobial activities and glycosylation in the gut
of neonates such Reg3g and Fut2. In adults, these IL-22-mediated changes contribute largely to the protection of the gut
from the harm of colitogenic bacteria.12–17,38 One of the most
studied IL-22 target genes is Reg3g, which has been shown to
protect the intestinal mucosa via the maintenance of microbial-
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host segregation by modulating the composition of the microbiota.12,13 On the other hand, Pham et al. have demonstrated
that Reg3g is dispensable in preventing Citrobacter rodentium
infection.17 Our data similarly showed that treatment with
rReg3g did not influence the outcome of experimental NEC.
The injection of pups with Reg3g as well as the neutralization
of this antimicrobial peptide during experimental NEC did not
reduce the expression of inflammatory factors or attenuate
epithelial cell damage.
To understand the influence of IL-22 treatment on the intestinal
microbiome, we analyzed the diversity of the microbial communities with 16S rRNA sequencing. The analysis did not show any
substantial impact of IL-22 treatment on the diversity and the
community composition of intestinal microbiota. These findings
were rather surprising, as previous studies conducted in adult
mice have shown the role of IL-22 in shaping the microbiome.17,38,39 This may be due to the profound differences in
the composition of the neonatal and the adult microbiomes. It is
well accepted that the first postnatal waves of colonizing microbes consist of facultative anaerobes, which are present in relatively high abundance in the intestine of neonates and prepare the
intestine for the colonization of more diverse, strict anaerobic species.31 Therefore, it is reasonable to speculate that the IL-22driven antimicrobial response in neonates does not affect the
facultative anaerobes that are present in the first days of life.
In conclusion, the current study demonstrates that the
neonatal period is associated with a reduced ability to produce
IL-22 in the intestine, which could render the premature infant
susceptible to the extensive epithelial cell damage seen during
NEC. In this study, we demonstrate that the exogenous administration of IL-22 results in the protection of the mucosal barrier
during experimental NEC by promoting intestinal epithelial cell
regeneration. Surprisingly, despite the transcriptional increase
of antimicrobial genes, the administration of IL-22 neonates
does not affect the composition of the intestinal microbiome.
Altogether, our pre-clinical data demonstrate that IL-22 treatment has the potential to be used as a therapeutic to attenuate
NEC in infants. This study demonstrated that similar to rodents,
the human premature intestine is characterized by the absence
of an IL-22 response during NEC, which might explain the
susceptibility of premature infants to the disease. Given the protective role of IL-22 in the experimental murine model, it seems
intuitive that the administration of IL-22 to infants displaying
NEC symptoms may prevent intestinal injury through the
enhancement of epithelial cell regeneration. This idea is supported by our in vitro experiments, which suggest that the epithelial cell response to IL-22 is at least conserved in premature
human intestinal organoids. Therefore, the exploration of the
protective role of IL-22 in clinical settings may set the ground
for a new therapeutic strategy to prevent NEC.
Limitations of study
The current study utilizes a neonatal mouse model of NEC to
study the effects of IL-22 treatment. A limitation of this study

(F) Boxplots of alpha diversity indices (Shannon, Chao1, and Simpson, respectively) reflecting the abundance and the diversity of the operational taxonomic units
(OTUs) in the colon contents of pups subjected to NEC and injected with either PBS or rIL-22. Data are displayed as mean ± SEM and were analyzed using MannWhitney test. *p < 0.05, **p < 0.01.
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is that these experiments do not establish the maximal tolerated dose of rIL-22 cytokine in the neonatal mouse NEC model,
which may provide additional insights for clinical translatability.
Given that clinical NEC represents a spectrum of disease, additional studies are necessary to investigate whether treatment
with rIL-22 can rescue experimental NEC and at which time
points. Another limitation of the study is that we did not monitor
the long-term effects of rIL-22 administration to neonatal mice
subjected to experimental NEC, which may require further
consideration.
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Antibodies
Rabbit Anti-OLFM4

Cell Signaling Technologies

Cat# 39141S; RRID: AB_2650511

Mouse Anti-PCNA

Santa Cruz

Cat# sc-56; RRID: AB_628110

Mouse Anti-Occludin

Invitrogen

Cat# 33-1500; RRID: AB_2533101

Hoechst 33342

Invitrogen

Cat# H1399

CD16/CD32 antibodies

Miltenyi Biotec

Cat# 130-102-429; RRID: AB_2660222

Zombie NIR Fixable Viability Dye

BioLegend

Cat# 423105

Anti-mouse CD45

BD Bioscience

Cat# 561487; RRID: AB_10697046

Anti-mouse IL22

BioLegend

Cat# 516409; RRID: AB_2563355

Anti-mouse Reg3g

Abcepta, Inc.

Cat# AP5606C; RRID: AB_10817069

Rabbit Immunoglobulin G

Sigma Aldrich

Cat# I5006; RRID: AB_1163659

Donkey anti-mouse 647

Invitrogen

Cat# A31571; RRID: AB_162542

Donkey anti-mouse 488

Invitrogen

Cat# A21202; RRID: AB_141607

Donkey anti-rabbit 488

Invitrogen

Cat# A21206; RRID: AB_2535792

Donkey anti-rabbit 594

Invitrogen

Cat# A21207; RRID: AB_141637

Biological samples
Human: healthy small intestine tissue

St. Louis Children’s Hospital

IRB Protocol 201804040

Mouse: healthy small intestine tissue

Washington University School of Medicine

Protocol 20190190

Recombinant Mouse IL-22

BioLegend

Cat# 576204

Recombinant Mouse Reg3g

R&D Systems

Cat# 8189-RG-050

Recombinant Human IL-22

BioLegend

Cat# 571302

Meso Scale Discovery

Cat# K152QPD-1

Chemicals, peptides, and recombinant proteins

Critical commercial assays
V-PLEX Mouse IL-1b Kit
Deposited data
Raw and analyzed data

This paper

N/A

RNA sequencing data

Deposited in Gene expression omnibus
Database: https://www.ncbi.nlm.nih.gov/
geo/

GEO Accession: GSE155172

Experimental models: Organisms/strains
C57BL/6 mice

The Jackson Laboratory

JAX Stock No. 000664

Villin cre mice

The Jackson Laboratory

JAX Stock No. 021504

IL22ra1fl/fl mice

Zheng et al., 2016

Gift from Dr. Jay Kolls

IL22/ mice

Trevejo-Nunez et al., 2016

Gift from Dr. Jay Kolls

Primers for RT-PCR analysis, see Table 1

This paper

N/A

Primer sequences for 16 s rRNA analysis,
see Table 2

This paper

N/A

Volocity v6.3.5

Quorum Technologies

https://quorumtechnologies.com

ZEN 2.3 pro, blue edition

Zeiss

https://www.zeiss.com/microscopy/us/
products/microscope-software/zen.html

ImageJ

Schneider et al., 2012

https://imagej.nih.gov/ij

FlowJo

TreeStar

https://www.flowjo.com/

Oligonucleotides

Software and algorithms

(Continued on next page)
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GraphPad Prism Software, Version 8.0

GraphPad

https://www.graphpad.com/

Abbott Nutrition

N/A

Esbilac Puppy Milk Replacer

PetAg

N/A

LWRN 50%CM

VanDussen, et al., 2019

N/A

Y-27632

R&D Systems

Cat# 1254/10

SB-431542

R&D Systems

Cat# 1614/10

Other
Similac Advance OptigroTM with Iron
infant formula

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to, and will be fulfilled by the lead contact, Misty
Good (mistygood@wustl.edu).
Materials availability
All unique/stable reagents generated in this study are available from the lead contact with a completed Materials Transfer Agreement.
Data and code availability
The datasets generated during this study are available at Gene Expression Omnibus (GEO): accession number GSE155172; Database: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE155172.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
C57BL/6 and villin cre mice were purchased from the Jackson Laboratory. IL22ra1fl/fl and IL22/ mice were obtained as a kind gift
from Dr. Jay Kolls and have been previously described.11,40,41 Mice were bred and maintained in a specific pathogen-free animal
facility at Washington University School of Medicine in St. Louis. All animal experiments were carried out in accordance with the
guidelines of the Institutional Animal Care and Use Committee (IACUC) (protocol #20190190).
Human specimens
Human small intestinal samples were obtained from infants undergoing intestinal resection for NEC or non-NEC conditions (controls)
at St. Louis Children’s Hospital. All the tissue specimens were obtained in a de-identified manner and processed as discarded tissue
via a waiver of consent with approval of the Washington University in St. Louis School of Medicine Institutional Review Board and in
accordance with the Washington University in St. Louis anatomical tissue procurement guidelines.
Induction of neonatal NEC
Experimental NEC induction was performed as previously described with slight modifications.34 Briefly, four-day-old neonatal mice
were separated from the dams, randomly assigned into experimental NEC groups and maintained in an infant incubator at 37 C. Agematched dam-fed control pups remained with their mothers. Experimental NEC was induced by oral gavage of a formula mixture
containing Similac Advance OptigroTM with Iron infant formula (Abbott Nutrition) and Esbilac canine milk replacer (ratio 2:1).
The formula was supplemented with 5 mg/g of body weight of lipopolysaccharide (Sigma Aldrich) and enteric bacteria isolated
from a human infant with NEC totalis, the most severe form of NEC.34 Pups subjected to this NEC protocol were fed six times daily
at regular intervals with the formula described above using 1.9 French Single-Lumen Silicon Peripherally Inserted Central Catheter
(PICC). The pups were subjected to 10 minutes of hypoxic stress twice a day in a hypoxia chamber (Billups-Rothenberg) containing
95% nitrogen and 5% oxygen. After 72 hours, pups were euthanized in accordance with IACUC policy. The terminal ileal samples
were collected during necropsy for analysis.
Animal treatments
Where indicated, dam-fed or experimental pups received either a daily intraperitoneal injection of PBS (vehicle control), recombinant
mouse IL-22 (100 mg/kg; Biolegend) or recombinant Reg3g (2 ng/pup; R&D Systems). Additionally, where indicated, dam-fed or
experimental pups received daily enteral gavage of anti-Reg3g neutralizing antibody (2 mg/gram body weight; Abcepta, Inc.) or rabbit
immunoglobulin G (IgG) (2 mg/g body weight; Sigma Aldrich).
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Histological assessment of the disease severity
Segments of terminal ilea were fixed in formalin, paraffin-embedded and stained with hematoxylin and eosin by the Digestive Disease
Research Core Center at the Washington University School of Medicine in St. Louis. Histological slides were scanned at the Washington University Center for Cellular Imaging using a Zeiss AxioScan Z1. Using ImageJ software, disease severity was assessed
based on the extent of histological lesions by an investigator blinded to the study conditions. Normal tissue sections were characterized by intact villi. Mild lesions were characterized by areas with mild villi destruction reflected by a substantial reduction of the villi
length. Severe lesions were defined as areas with complete villus necrosis and significant disruption to the architecture of the villi
(Figure S7). The severity score reflects the extent of the lesion as a percentage of the total length of the histological specimen.
METHOD DETAILS
Immunofluorescence
Tissue sections (5 mm) were deparaffinized in xylenes, rehydrated in isopropanol, and boiled in antigen unmasking solution (Vector
Laboratories). After washing with water, the tissues were blocked in Tris Buffered Saline (Boston BioProducts) supplemented with
1% bovine serum albumin (BSA, Sigma), 10% normal donkey serum (NDS, Sigma) and 0.1% Tween-20 (Sigma) for an hour at
room temperature. Tissue specimens were stained overnight with a rabbit anti-OLMF4 (Cell Signaling Technologies), mouse antiPCNA (Santa Cruz) or mouse anti-Occludin (Invitrogen) diluted 100X in the blocking buffer at 4 C. Following washing in Tris Buffered
Saline supplemented with 1% bovine serum albumin and 0.1% Tween-20, the tissue sections were incubated for an hour at room
temperature with secondary antibodies (donkey anti-mouse 647, donkey anti-mouse 488, donkey anti-rabbit 488 or donkey anti-rabbit 594, Invitrogen) diluted 200X in blocking buffer. Nuclear staining was performed using Hoechst 33342 (Invitrogen) for 5 minutes,
and slides were mounted with Prolong Gold (Thermo Fisher). Images were acquired using either a Leica SP8 tandem scanning
confocal and processed using Volocity (v6.3.5, Quorum) or a Zeiss Axio Observer.Z1 microscope and processed using ZEN 2.3
pro, blue edition software (Zeiss). Image analysis was performed with NIH ImageJ software. The number of PCNA stained nuclei
were counted in 15 to 20 intestinal crypts in each sample. The data were displayed as the average of PCNA+ cells per crypt.
Lamina propria cell isolation and flow cytometry
Lamina propria cells were isolated from the last 5 cm of the distal small intestine. Briefly, intestinal specimens were opened longitudinally, washed in ice cold phosphate-buffered saline (PBS) and incubated in 2 mM EDTA/PBS for 30 minutes at 4 C in a rotating
device. After transferring the tissue samples to ice cold PBS, the epithelial cells were removed by pipetting 3 times up and down.
The remaining intestinal tissues were digested in RPMI supplemented with 2.5% fetal bovine serum (FBS), 1 mg/ml collagenase
type 4 (Worthington-Biochem) and 0.05 mg/ml DNase (Sigma) at 4 C for 40 minutes in an orbital shaker. The digestion was quenched
with RPMI supplemented with 10% FBS and passed successively through 70 mm and 40 mm strainers to obtain a single cell suspension. Cells were stimulated with ionomycin phorbol-12-myristate 13-acetate activation cocktail (Biolegend) in the presence of BD
GolgiStop (BD Biosciences) for 4 hours in RPMI supplemented with 10% FBS. After washing the cells in RPMI supplemented
with 10% FBS, they were resuspended in PBS and stained with Zombie NIR Fixable Viability dye (BioLegend) following the manufacturer’s instructions. After washing in FACS buffer (PBS supplemented with 3% FBS), the cells were sequentially blocked on ice
with CD16/CD32 antibodies (Miltenyi Biotec) for 10 minutes and stained with of 200X diluted anti-mouse CD45 antibody (BD Bioscience) for 20 minutes. Intracellular staining of IL-22 was carried out with a 100X diluted anti-mouse IL-22 antibody (Biolegend) using
BD Biosciences Cytofix/Cytoperm and Perm/Wash solutions following the manufacturer’s protocol. Cell acquisition was carried out
using MACSQuant Analyzer 10 (Miltenyi Biotec) and the data were analyzed FlowJo software (TreeStar).
Human and murine intestinal enteroid culture
Human intestinal tissue biopsies were obtained from premature infants with approval from the Washington University in St. Louis
Institutional Review Board (no. 201804040). Intestinal tissue samples were digested Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS) and 1 mg/ml of collagenase I (Invitrogen, Waltham, MA) for 10 minutes at
37 C. The enzymatic digestion was followed by a mechanical dissociation. The resulting crypts were filtered through a 70-mm cell
strainer, washed in DMEM supplemented with 10% FBS and resuspended in growth factor-reduced Matrigel (Becton Dickinson,
Franklin Lakes, NJ). The resuspended crypts were seeded into culture plates and cultured in 50% L-WRN conditioned medium supplemented with 10 mM Y-27632 and SB 202190 (R&D Systems). After 7 days, the resulting enteroids were treated with recombinant
human IL-22 (Biolegend) at 1, 10 and 100 ng/ml for 24 hours.
Murine enteroids were generated from isolated crypts from the small intestines of adult (4 weeks) or neonatal mice (7 days) as previously described.42 The crypts were resuspended in Matrigel and cultured for 24 hours in 50% L-WRN conditioned medium43 supplemented with 10 mM Y-27632 and SB 202190. The following day, the enteroids were differentiated in Advanced DMEM/F12 medium
(GIBCO) supplemented with 2 mM GlutaMax (Invitrogen), 10 mM HEPES (Thermo Fisher Scientific). For differentiation, the enteroids
were cultured in differentiation media consisting of basal culture medium with (1X) N2 supplement (Invitrogen), (1X) B27 supplement
(Invitrogen), and 1 mM N-acetylcysteine (Sigma Aldrich), 50 ng/mL murine recombinant EGF (Invitrogen), 10 ng/mL murine recombinant
Noggin (PeproTech), 10 ng/mL human recombinant R-spondin 1 (Miltenyi Biotec). After 4 days in the differentiation medium, the enteroids were treated with 2 ng/ml of recombinant mouse IL-22 (Biolegend) for 24 hours before being further processed.
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Quantitative PCR
Intestinal enteroids were directly lysed in Trizol (Thermo Fisher Scientific) by pipetting up and down, while intestinal tissue samples were
homogenized in Trizol using Tissue Lyzer II (QIAGEN). Total RNA was extracted according to the manufacturer’s instructions and was
quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific). RNA was converted into cDNA using QuantiTech Reverse
Transcription Kit (QIAGEN). Quantitative real-time PCR (qRT-PCR) was performed on the CFX ConnectTM Real-Time PCR Detection
System (Bio-Rad) using IQ SYBR Green Supermix and the primers listed in Table 1. The reaction protocol includes an initial preincu-

Table 1. Primers used in the present study for RT-PCR analysis of gene expression
Gene

Species Forward primer

Tm forward, C Reverse primer

Tm reverse, C Amplicon size, bp

Rpl0

mouse

GGCGACCTGGAAGTCCAACT

59.7

58.7

Il1b

mouse

AGTGTGGATCCCAAGCAATACCCA 60.4

TGTCCTGACCACTGTTGTTTCCCA 60.5

175

Reg3g

mouse

GTACCCTGTCAAGAGCCTCA

56.3

TGTGGGGAGAATGTTCCCTT

182

Il22

mouse

CGACCAGAACATCCAGAAGAA

54.5

GAGACATAAACAGCAGGTCCA

54.5

110

Il22ra1

mouse

CAGCGGATCACCCAGAAGTT

57.4

CGTGGAGCTCTAAGCGGTAG

57.2

298

Cxcl1

mouse

TGGCTGGGATTCACCTCAAG

57.2

CCGTTACTTGGGGACACCTT

57.1

179

Cxcl2

mouse

CCAGACAGAAGTCATAGCCACT

56.3

GGCACATCAGGTACGATCCA

56.9

217

Fut2

mouse

CAGAAGAGCCATGGCGAGTG

58.4

CGTTGCTGGAGGTGGATGAT

57.4

102

Retnlb

mouse

CCATTTCCTGAGCTTTCTGG

53.6

AGCACATCCAGTGACAACCA

56.8

320

RETNLB human

AGCTCTCGTGTGCTAGTGTC

56.6

TGAACATCCCACGAACCACA

56.7

109

REG3G

human

TATCTGTGTGTCCTCCCGCT

57.8

AGGAAAGCAGCATCCAGGAC

57.5

118

IL22

human

AACCCCCTTTCCCTGCTAGA

58.1

ACGCAGGGGTTCATTTGGAA

57.4

119

ACGTACGGAGAGAGGGACTG

57.9

GAGGGTAGTGTGCTGCAGAG

57.6

189

IL22RA1 human

CCATCAGCACCACAGCCTTC

56.1

143

Tm, melting temperature

bation at 95 C for 3 minutes to denature the DNA, with amplification performed for 40 cycles (10 s at 95 C, 10 s at 55 C and 30 s at
72 C). Gene expression levels were expressed as normalized values relative to the housekeeping gene Rplo.
V-plex assay
A mouse IL-1b V-plex assay (Meso Scale Diagnostics) was performed by the Immunomonitoring Laboratory (IML) at Washington University.
RNA sequencing
Total RNAs were isolated from the terminal ileum of 4 week old IL22ra1fl/fl; Vil cre+ and IL22ra1fl/fl; Vil cre- mice. In addition, total RNAs
were also isolated from intestinal enteroids cultured from the small intestine of WT mice which have treated for 24 hours with PBS or
100 ng/ml of mouse IL-22. mRNA was purified with oligo-dT beads, and used for cDNA synthesis with random primers after a fragmentation step with magnesium followed by heat-catalyzed hydrolysis. The cDNA 30 ends were adenylated, followed by adaptor ligation and a 15-cycle PCR to enrich DNA fragments. cDNA libraries were generated using a v2 Guide Quantification of cDNA libraries
was performed by using Kapa Biosystems primer premix kit with Illumina-compatible DNA primers. The cDNA libraries were pooled
at a final concentration 1.8 pM. Single-read sequencing was performed on Illumina Genome Analyzer IIx and NextSeq 500. The raw
reads were processed following the methods described by Kumar et al.44 to generate Reads per Mapped Million per Kilobase (RPKM)
values. RNA sequencing data is deposited in Gene Expression Omnibus (Geo); accession number GSE155172.
16S rRNA microbial community analysis
Mouse fecal samples were collected from the distal portion of the colon during necropsy. DNA was isolated using QIAamp PowerFecal Pro stool DNA extraction kit (QIAGEN) and the 16S rRNA sequencing and analysis were performed by Genome Technology
Access Center at Washington University in St. Louis. Seven PCR amplicons representative of all nine 16S variable regions using
the primers indicated in Table 2 were generated using the Fluidigm Access Array System. Reaction mixture components (all from
Table 2. Primers sequences associated with the seven PCR amplicons covering nine variable
regions in the bacterial 16S rRNA gene
Name

Sequence

V1-V2_F

TCGTCGGCAGCGTCAGAGTTTGATCCTGGCTCAG

V2_F

TCGTCGGCAGCGTCAGYGGCGIACGGGTGAGTAA
(Continued on next page)
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Table 2.

Continued

Name

Sequence

V3_2_F

TCGTCGGCAGCGTCCCTACGGGAGGCAGCAG

V4_F

TCGTCGGCAGCGTCGTGCCAGCMGCCGCGGTAA

V5-V6_F

TCGTCGGCAGCGTCAGGATTAGATACCCTGGTA

V6_1_F

TCGTCGGCAGCGTCAAACTCAAAKGAATTGACGG

V7-V8_F

TCGTCGGCAGCGTCGYAACGAGCGCAACCC

V1-V2_R

GTCTCGTGGGCTCGGTGCTGCCTCCCGTAGGAGT

V2_R

GTCTCGTGGGCTCGGCYIACTGCTGCCTCCCGTAG

V3_2_R

GTCTCGTGGGCTCGGGTATTACCGCGGCTGCTGG

V4_R

GTCTCGTGGGCTCGGGGACTACHVGGGT
WTCTAAT

V5-V6_R

GTCTCGTGGGCTCGGCRRCACGAGCTGACGAC

V6_1_R

GTCTCGTGGGCTCGGACGAGCTGAC
GACARCCATG

V7-V8_R

GTCTCGTGGGCTCGGGACGGGCGGTGWGTRC

Fluidigm) included 10X FastStart High Fidelity buffer without MgCl, 25mM MgCl, dimethyl sulfoxide, 10 mM PCR Grade Nucleotide
Mix, 0.05 U/mL of 5U/mL FastStart High Fidelity Enzyme Blend, 20X Access Array Loading Reagent, 1 mL DNA, and molecular grade
water. The BioMark HD system from Fluidigm was employed for PCR amplification. Reaction products were indexed with unique 10
base pair sequences via 7 rounds of PCR in order to combine each index sequence. 48 sample libraries were constructed via sample
pooling and bead purification (Fluidigm) used for cleaning as in Schriefer et al.45 Illumina MiSeq sequencer (2 3 150 base pair kit) was
used for library sequencing. Demultiplexed reads from the 7 amplicons were analyzed using the MVRSION pipeline described by
Schriefer et al.,45 to generate a list of microbial species with their corresponding number of reads for each sample. Default parameters
were employed for the MVRSION analysis in conjunction with the Silva 16S database. Diversity analysis was run for the following
sample groupings: Experimental NEC + PBS control (NEC + PBS) versus NEC + rIL-22.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses with Mann Whitney U-tests, analysis of variance, and two-tailed Student’s t tests were performed where indicated using GraphPad Prism software version 8.0. Statistical significance was set at a P value of < 0.05.
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